睿知中国疾病研究地图
候选清单0

济南山东大学

山东大学齐鲁医院

Qilu Hospital of Shandong University

在本站收录的 53 种疾病中,这家医院列在其中 38 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

山东大学齐鲁医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma4 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma31 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma80 篇牵头论文牵头 1 项开放试验
  4. 胃癌Stomach cancer80 篇牵头论文牵头 15 项开放试验
  5. 肝母细胞瘤Hepatoblastoma0 篇牵头论文
  6. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  7. 脊索瘤Chordoma0 篇牵头论文
  8. 骨肉瘤Osteosarcoma16 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  10. 神经母细胞瘤Neuroblastoma5 篇牵头论文
  11. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  12. 多发性骨髓瘤Multiple myeloma3 篇牵头论文牵头 1 项开放试验
  13. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia2 篇牵头论文
  14. 再生障碍性贫血Aplastic anaemia3 篇牵头论文
  15. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
  16. β 地中海贫血Beta thalassaemia0 篇牵头论文
  17. 血友病 AHaemophilia A2 篇牵头论文
  18. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder7 篇牵头论文
  19. 重症肌无力Myasthenia gravis6 篇牵头论文
  20. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis8 篇牵头论文
  21. 肝包虫病Hepatic echinococcosis1 篇牵头论文
  22. 特发性肺纤维化Idiopathic pulmonary fibrosis4 篇牵头论文
  23. 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis1 篇牵头论文
  24. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis13 篇牵头论文
  25. 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文
  26. 法布雷病Fabry disease1 篇牵头论文
  27. 庞贝病Pompe disease2 篇牵头论文
  28. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  29. 白塞病Behçet disease1 篇牵头论文
  30. Alport 综合征Alport syndrome1 篇牵头论文
  31. IgA 肾病IgA nephropathy2 篇牵头论文
  32. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
  33. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
  34. 先天性膈疝Congenital diaphragmatic hernia1 篇牵头论文
  35. 先天性巨结肠Hirschsprung disease3 篇牵头论文
  36. 遗传性血管性水肿Hereditary angioedema1 篇牵头论文
  37. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文
  38. Leber 遗传性视神经病变Leber hereditary optic neuropathy3 篇牵头论文

未列出的收录疾病:非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、大动脉炎、戈谢病、尼曼-匹克病 C 型、成骨不全症、遗传性大疱性表皮松解症、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 1120222023: 0020232024: 0020242025: 002025

济南有 2 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题放疗技术EB病毒与筛查复发与转移
论文中的科室耳鼻喉/头颈外科放疗科肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 31 篇,占 1.1%。

牵头论文
31
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 5520222023: 5520232024: 4420242025: 882025

济南有 6 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
    分期
    不分期
    开始
    2024-12
    登记号
    NCT07430579

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:山东大学第二医院;另有 1 家列出的医院为研究中心济南

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗早期发现与内镜影像与人工智能
论文中的科室放疗科消化/肝病科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文31
  1. ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1-Mediated Lipid Metabolic Reprogramming.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. tRNA-Derived Fragment tRF-22 Promotes Immunosuppression by Inhibiting HnRNPAB Ubiquitination in Esophageal Squamous Cell Carcinoma.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Ivor Lewis minimally invasive oesophagectomy versus McKeown approach: short-term benefits and mid-term equivalence in a randomized trial for oesophageal squamous cell carcinoma.2026Surgical endoscopyRCT免费全文
  4. Value of Computed Tomography Scan for Detecting Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma.2025Annals of surgical oncology
  5. High MRPL12 expression drives esophageal cancer proliferation, invasion and migration.2025Bulletin du cancer
  6. The GNL3L-MDM2 Interaction Drives Esophageal Squamous Cell Carcinoma Progression.2025Cancer medicine免费全文
  7. Harnessing NKG2D CAR-T cells with radiotherapy: a novel approach for esophageal squamous cell carcinoma treatment.2025Frontiers in immunology免费全文
  8. tRNA-derived fragment tRF-24 drives CELF1 phase separation to promote oncogenic splicing in esophageal squamous cell carcinoma.2025Journal of experimental & clinical cancer research : CR免费全文
  9. CICADA: a circRNA effort toward the ghost proteome.2025Nucleic acids research免费全文
  10. LAMA3 overexpression enhances proliferation, migration and invasion in esophageal squamous cell carcinoma based on bioinformatics and experimental validation.2025Scientific reports免费全文
  11. Artificial intelligence-aided optical biopsy improves the diagnosis of esophageal squamous neoplasm.2025World journal of gastroenterology免费全文
  12. T cell-related circRNA pairs to predict prognosis of patients with esophageal squamous cell carcinoma.2024International immunopharmacology
  13. CT-based delta-radiomics nomogram to predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma patients.2024Journal of translational medicine免费全文
  14. Genetic and molecular characterization of metabolic pathway-based clusters in esophageal squamous cell carcinoma.2024Scientific reports免费全文
  15. Risk factors for lymph node metastasis in superficial esophageal squamous cell carcinoma.2024World journal of gastroenterology免费全文
  16. Unveiling the prognostic significance of SOX5 in esophageal squamous cell carcinoma: a comprehensive bioinformatic and experimental analysis.2023Aging免费全文
  17. A novel diagnostic signature of circulating tsRNAs and miRNAs in esophageal squamous cell carcinoma detected with a microfluidic platform.2023Analytica chimica acta
  18. Development and Validation of Esophageal Squamous Cell Carcinoma Risk Prediction Models Based on an Endoscopic Screening Program.2023JAMA network open免费全文
  19. Optimal concentration of Lugol's solution for detecting early esophageal carcinoma: A randomized controlled trial.2023Journal of gastroenterology and hepatologyRCT
  20. KLF5 promotes esophageal squamous cell cancer through the transcriptional activation of FGFBP1.2023Medical oncology (Northwood, London, England)免费全文
  21. BTN3A1 promotes tumor progression and radiation resistance in esophageal squamous cell carcinoma by regulating ULK1-mediated autophagy.2022Cell death & disease免费全文
  22. Construction and Evaluation of a Risk Score Model for Lymph Node Metastasis-Associated Circadian Clock Genes in Esophageal Squamous Carcinoma.2022Cells免费全文
  23. Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma.2022Current oncology (Toronto, Ont.)免费全文
  24. Esophageal wall thickness on CT scans: can it predict the T stage of primary thoracic esophageal squamous cell carcinoma?2022Esophagus : official journal of the Japan Esophageal Society
  25. Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites.2022Frontiers in immunology免费全文
  26. A nomogram for screening esophageal squamous cell carcinoma based on environmental risk factors in a high-incidence area of China: a population-based case-control study.2021BMC cancer免费全文
  27. Syntaphilin downregulation facilitates radioresistance via mediating mitochondria distribution in esophageal squamous cell carcinoma.2021Free radical biology & medicine
  28. Screening of tumor grade-related mRNAs and lncRNAs for Esophagus Squamous Cell Carcinoma.2021Journal of clinical laboratory analysis免费全文
  29. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.2021Radiation oncology (London, England)免费全文
  30. Integrated bioinformatics analysis of differentially expressed genes and immune cell infiltration characteristics in Esophageal Squamous cell carcinoma.2021Scientific reports免费全文
  31. KIF4A enhanced cell proliferation and migration via Hippo signaling and predicted a poor prognosis in esophageal squamous cell carcinoma.2021Thoracic cancer免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection进行中,不再招募NCT07757906牵头方不分期2026-08 启动
  2. Neoadjuvant Immunotherapy to ESCC已撤回NCT04625543牵头方II期2020-12 启动
  3. Artificial Intelligence for Early Diagnosis of Esophageal Squamous Cell Carcinoma已完成NCT03759756牵头方(推断)2018-12 启动
  4. Early Detection of Head and Neck Superficial Squamous Cell Carcinoma in Patients With Esophagus Squamous Cell Carcinoma状态不明NCT03700398牵头方(推断)不分期2017-10 启动
  5. Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine Staining已完成NCT03180944牵头方(推断)II期2017-09 启动
  6. Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma正在招募NCT07430579研究中心不分期2024-12 启动
  7. Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).状态不明NCT04063683研究中心II期2019-10 启动
  8. A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC已完成NCT02721563研究中心IV期2016-02 启动
PubMed 以外找到的论文(未计入)22
  1. 104P ARL5B drives esophageal squamous cell carcinoma progression via ROCK1-SREBP1-mediated metabolic reprogramming2025ESMO Open论文
  2. 399P ARL5B drives esophageal squamous cell carcinoma progression via ROCK1-SREBP1-mediated metabolic reprogramming2025Annals of Oncology论文
  3. Additional file 1 of tRNA-derived fragment tRF-24 drives CELF1 phase separation to promote oncogenic splicing in esophageal squamous cell carcinoma2025Figshare论文
  4. Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Survival results of a phase II trial.2025Journal of Clinical Oncology会议摘要
  5. tRNA-derived fragment tRF-24 drives CELF1 phase separation to promote oncogenic splicing in esophageal squamous cell carcinoma2025Figshare补充材料
  6. 103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study2024Immuno-Oncology Technology论文
  7. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncology会议摘要
  8. First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multicenter phase II trial.2024Journal of Clinical Oncology会议摘要
  9. 95P A single-arm, multicenter phase II trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)2023Immuno-Oncology Technology论文
  10. SHR-1701 plus chemotherapy as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2023Journal of Clinical Oncology会议摘要
  11. TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase Ⅱ trial.2023Journal of Clinical Oncology会议摘要
  12. 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study2022Annals of Oncology论文
  13. 164P TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter phase Ⅱ trial2022Immuno-Oncology Technology论文
  14. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  15. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figshare数据集
  16. Association of Esophageal Squamous Cell Carcinoma With the Interaction Between Poor Oral Health and Single Nucleotide Polymorphisms in Regulating Cell Cycles and Angiogenesis: A Case-Control Study in High-Incidence Chinese2022Cancer Control论文
  17. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.2022Journal of Clinical Oncology会议摘要
  18. Effect of Long Term Prediagnostic Aspirin Intake on the Prognosis of Esophageal Squamous Cell Carcinoma Receiving Radical Surgery2021Research Square预印本
  19. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本
  20. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本
  21. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase Ⅱ clinical trial.2021Journal of Clinical Oncology会议摘要
  22. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 80 篇,占 0.5%。

牵头论文
80
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 111120222023: 232320232024: 141420242025: 19192025

济南有 6 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
    分期
    II期
    开始
    2024-07
    登记号
    NCT06454578

    年龄 18 岁 至 未注明(登记的条件)

    牵头:山东大学齐鲁医院济南

  2. 即将招募
    Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
    分期
    不分期
    开始
    2025-06
    登记号
    NCT07010588

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京大学人民医院;另有 8 家列出的医院为研究中心北京、哈尔滨、武汉、济南、西安、重庆、长春、青岛

  3. 即将招募
    TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
    分期
    II期
    开始
    2025-12
    登记号
    NCT07350070

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属同济医院;另有 4 家列出的医院为研究中心南宁、武汉、济南、福州、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科消化/肝病科影像/核医学科病理/检验科
牵头的论文80
  1. Reduced visceral adipose tissue area linked to early recurrence in HCC patients with HBV: a parallel mediation analysis.2026Abdominal radiology (New York)
  2. The landscape of gut microbiota in hepatocarcinogenesis: a comprehensive review of pathogenesis and therapeutic interventions.2026International journal of surgery (London, England)免费全文
  3. Impact of thrombocytopenia and coagulopathy on partial hepatectomy and Hassab's operation in patients with cirrhosis: a multicenter retrospective cohort study.2025Annals of medicine免费全文
  4. Temporal Dynamics of Somatic Mutations in Tumor and Plasma Samples From Hepatocellular Carcinoma Patients Pre- and Post-Radioactive Particle Implantation: A Whole-Exome Sequencing Study.2025Biotechnology and applied biochemistry
  5. Hypoxia-Induced Creatine Uptake Reprograms Metabolism to Antagonize PARP1-Mediated Cell Death and Facilitate Tumor Progression in Hepatocellular Carcinoma.2025Cancer research
  6. Targeting FAM111B attenuates mitophagy and increases the sensitivity to lenvatinib treatment by increasing MFN2 stability in hepatocellular carcinoma.2025Cell death & disease免费全文
  7. The Role of the Hexosamine-Sialic Acid Metabolic Pathway Mediated by GFPT1/NANS in c-Myc-Driven Hepatocellular Carcinoma.2025Cellular and molecular gastroenterology and hepatology免费全文
  8. Hyaluronan-mediated motility receptor regulating the Wnt/β-catenin signaling resulting in hepatocellular carcinoma by inhibiting the phosphorylation activity of GSK-3β.2025European journal of medical research免费全文
  9. An umbrella review of the association between dietary factors and hepatocellular carcinoma risk.2025Food & function
  10. Multi-parameter MRI-based model for the prediction of early recurrence of hepatitis B-associated hepatocellular carcinoma after microwave ablation.2025Frontiers in cellular and infection microbiology免费全文
  11. SLC12A7 serves as a prognostic and immunotherapeutic biomarker identified by multi-omics analysis.2025Frontiers in immunology免费全文
  12. Protective Effects of GalNac-Modified Red Blood Cell-Derived Extracellular Vesicles Against Liver Diseases.2025International journal of nanomedicine免费全文
  13. Systemic therapy plus HAIC versus systemic therapy for hepatocellular carcinoma: a systematic review and meta-analysis.2025International journal of surgery (London, England)免费全文
  14. Hyperspectral Imaging for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Differentiation.2025Journal of biophotonics
  15. Comparison of tenofovir versus entecavir for preventing hepatocellular carcinoma in chronic hepatitis B patients: an umbrella review and meta-analysis.2025Journal of cancer research and clinical oncology免费全文
  16. Targeting SAMD1 enhances the effect of anti-PD-1 plus lenvatinib therapy in hepatocellular carcinoma by increasing ferroptosis sensitivity and immune response.2025Metabolism: clinical and experimental
  17. Epigenetic modulation with nanosatellite triggers tumoricidal immunity for hepatocellular carcinoma treatment.2025Nature communications免费全文
  18. Targeting ferroptosis: the role of non-coding RNAs in hepatocellular carcinoma progression and therapy.2025Naunyn-Schmiedeberg's archives of pharmacology
  19. MYCBP2-mediated HNF4α ubiquitination reprogrammed lipid metabolism in MASH-associated hepatocellular carcinoma.2025Oncogene
  20. Role of endothelial cell markers in prognosis of hepatocellular carcinoma: Integrating bioinformatics analysis and experimental validation.2025PloS one免费全文
  21. FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers.2025Scientific reports免费全文
  22. Multiparametric MRI manifestations of the spontaneous intratumoral coagulative necrosis in HCC.2024Abdominal radiology (New York)
  23. Research on multi-model imaging machine learning for distinguishing early hepatocellular carcinoma.2024BMC cancer免费全文
  24. Brusatol improves the efficacy of sorafenib in Huh7 cells via ferroptosis resistance dependent Nrf2 signaling pathway.2024Biochemical and biophysical research communications
  25. DAP3 promotes mitochondrial activity and tumour progression in hepatocellular carcinoma by regulating MT-ND5 expression.2024Cell death & disease免费全文
  26. Gastrointestinal Bleeding Was Diagnosed as Small Intestinal Metastasis of Hepatocellular Carcinoma by Double-Balloon Enteroscopy.2024Digestive diseases and sciences
  27. The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis.2024Expert review of anticancer therapy
  28. Hypomethylation of glycine dehydrogenase promoter in peripheral blood mononuclear cells is a new diagnostic marker of hepatitis B virus-associated hepatocellular carcinoma.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  29. MCM4 potentiates evasion of hepatocellular carcinoma from sorafenib-induced ferroptosis through Nrf2 signaling pathway.2024International immunopharmacology
  30. Role of hepatitis B core-related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta-analysis.2024Journal of gastroenterology and hepatology
  31. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.2024Journal of hepatology
  32. Ficolin-3 induces apoptosis and suppresses malignant property of hepatocellular carcinoma cells via the complement pathway.2024Life sciences免费全文
  33. Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity.2024Science immunology
  34. TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-κB pathways.2024Scientific reports免费全文
  35. Development of a short-term nutritional risk prediction model for hepatocellular carcinoma patients: a retrospective cohort study.2024Scientific reports免费全文
  36. Development and External Validation of a Nomogram Including Body Composition Parameters for Predicting Early Recurrence of Hepatocellular Carcinoma After Hepatectomy.2023Academic radiology
  37. LAMP2A, LAMP2B and LAMP2C: similar structures, divergent roles.2023Autophagy免费全文
  38. Comparison of clinicopathologic characteristics among patients with HBV-positive, HCV-positive and Non-B Non-C hepatocellular carcinoma after hepatectomy: a systematic review and meta-analysis.2023BMC gastroenterology免费全文
  39. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.2023Cancer immunology, immunotherapy : CII免费全文
  40. Diacylglycerol lipase alpha promotes hepatocellular carcinoma progression and induces lenvatinib resistance by enhancing YAP activity.2023Cell death & disease免费全文
  41. Transcription factor Zhx2 is a checkpoint that programs macrophage polarization and antitumor response.2023Cell death and differentiation免费全文
  42. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.2023Clinical and experimental medicine
  43. Systemic therapy with or without locoregional therapy for advanced hepatocellular carcinoma: A systematic review and network meta-analysis.2023Critical reviews in oncology/hematology
  44. Impact of particle size of multivesicular liposomes on the embolic and therapeutic effects in rabbit VX2 liver tumor.2023Drug delivery免费全文
  45. Adipose distribution patterns as prognostic factors in patients with HCC: A systematic review and meta-analysis.2023European journal of radiology
  46. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.2023Expert review of gastroenterology & hepatology
  47. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis.2023Expert review of gastroenterology & hepatology
  48. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis.2023Expert review of gastroenterology & hepatology
  49. The association of fatty liver and risk of hepatocellular carcinoma in HBV or HCV infected individuals: a systematic review and meta-analysis.2023Expert review of gastroenterology & hepatology
  50. Development and validation of prognostic risk prediction models for hepatocellular carcinoma patients treated with immune checkpoint inhibitors based on a systematic review and meta-analysis of 47 cohorts.2023Frontiers in immunology免费全文
  51. New techniques: a roadmap for the development of HCC immunotherapy.2023Frontiers in immunology免费全文
  52. HMGCL-induced β-hydroxybutyrate production attenuates hepatocellular carcinoma via DPP4-mediated ferroptosis susceptibility.2023Hepatology international免费全文
  53. Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysis.2023Immunotherapy
  54. Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades.2023Journal of cancer research and clinical oncology免费全文
  55. Construction of an anoikis‒related prognostic signature to predict immunotherapeutic response and prognosis in hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  56. Gastrointestinal: Pitfalls of an abruptly elevated alpha-fetoprotein in a chronic hepatitis B carrier.2023Journal of gastroenterology and hepatology
  57. The Association of Glycemic Index, Glycemic Load, and Daily Carbohydrates Intake with the Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2023Nutrition and cancer
  58. Decreased GPX3 mRNA level in peripheral blood mononuclear cells is associated with HBV-related hepatocellular carcinoma.2023Transactions of the Royal Society of Tropical Medicine and Hygiene
  59. MYC Promotes LDHA Expression through MicroRNA-122-5p to Potentiate Glycolysis in Hepatocellular Carcinoma.2022Analytical cellular pathology (Amsterdam)免费全文
  60. The influence of transarterial chemoembolization on serum levels of soluble programed cell death ligand-1 in advanced hepatocellular carcinoma patients.2022Asia-Pacific journal of clinical oncology
  61. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.2022Biochemical and biophysical research communications
  62. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.2022Cancer immunology, immunotherapy : CII免费全文
  63. The causal relationship between white blood cell counts and hepatocellular carcinoma: a Mendelian randomization study.2022European journal of medical research免费全文
  64. MRI-based preoperative markers combined with narrow-margin hepatectomy result in higher early recurrence.2022European journal of radiologyRCT
  65. The Prognostic Value of Natural Killer Cells and Their Receptors/Ligands in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2022Frontiers in immunology免费全文
  66. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  67. Prognostic potential of the small GTPase Ran and its methylation in hepatocellular carcinoma.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  68. Integrin alpha 6 is upregulated and drives hepatocellular carcinoma progression through integrin α6β4 complex.2022International journal of cancer免费全文
  69. Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis.2022Journal of gastroenterology and hepatology
  70. Dual roles of WISP2 in the progression of hepatocellular carcinoma: implications of the fibroblast infiltration into the tumor microenvironment.2021Aging免费全文
  71. ST8SIA6-AS1 promotes the development of hepatocellular carcinoma cells through miR-338-3p/NONO Axis.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  72. 5-Aza-2'-deoxycytidine may enhance the frequency of T regulatory cells from CD4+ naïve T cells isolated from the peripheral blood of patients with chronic HBV infection.2021Expert review of clinical immunology
  73. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.2021Frontiers in immunology免费全文
  74. Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis.2021Hepatology international
  75. Effects of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α overexpression on hepatocellular carcinoma survival: A systematic review with meta-analysis.2021Journal of gastroenterology and hepatology
  76. Hypermethylation of secreted frizzled related protein 2 gene promoter serves as a noninvasive biomarker for HBV-associated hepatocellular carcinoma.2021Life sciences
  77. Tumor attenuation and quantitative analysis of perfusion parameters derived from tri-phasic CT scans in hepatocellular carcinoma: Relationship with histological grade.2021Medicine免费全文
  78. Repeated postoperative adjuvant TACE after curative hepatectomy improves outcomes of patients with HCC.2021Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  79. Value of perfusion parameters histogram analysis of triphasic CT in differentiating intrahepatic mass forming cholangiocarcinoma from hepatocellular carcinoma.2021Scientific reports免费全文
  80. LncRNA ZEB1-AS1 regulates hepatocellular carcinoma progression by targeting miR-23c.2021World journal of surgical oncology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection正在招募NCT06454578牵头方II期2024-07 启动
  2. Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma状态不明NCT05327907牵头方2020-11 启动
  3. Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular Carcinoma已完成NCT05017922牵头方不分期2017-01 启动
  4. Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma状态不明NCT06571396牵头方2014-04 启动
  5. TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension即将招募NCT07350070研究中心II期2025-12 启动
  6. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk即将招募NCT07010588研究中心不分期2025-06 启动
  7. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  8. TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma状态不明NCT01605734研究中心II期2012-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 80 篇,占 0.8%。

牵头论文
80
2021–2025 年
牵头试验
41
任何状态,ClinicalTrials.gov
牵头的开放试验
15
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 141420222023: 202020232024: 161620242025: 18182025

济南有 8 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 15

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer
    分期
    II期
    开始
    2026-01
    登记号
    NCT07537348

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:山东大学齐鲁医院济南

  2. 正在招募
    Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer
    分期
    II期
    开始
    2026-01
    登记号
    NCT07537361

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:山东大学齐鲁医院济南

  3. 正在招募
    Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer
    分期
    不分期
    开始
    2026-05
    登记号
    NCT07635836

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东大学齐鲁医院济南

  4. 正在招募
    Exploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on Multiomics
    分期
    未注明
    开始
    2024-03
    登记号
    NCT05812287

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东大学齐鲁医院济南

  5. 正在招募
    Integrative Analysis of Exosome-Mediated Single-Cell Transcriptomics and Proteomics in Gastric Cardia Cancer
    分期
    未注明
    开始
    2024-12
    登记号
    NCT06702891

    年龄 18 岁 至 未注明(登记的条件)

    牵头:山东大学齐鲁医院济南

  6. 正在招募
    First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
    分期
    II期
    开始
    2024-10
    登记号
    NCT06730373

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东大学齐鲁医院;另有 7 家列出的医院为研究中心临沂、济南、淄博、烟台、郑州、青岛

  7. 正在招募
    Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer
    分期
    不分期
    开始
    2024-12
    登记号
    NCT06748352

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:山东大学齐鲁医院济南

  8. 正在招募
    Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
    分期
    I/II期
    开始
    2024-09
    登记号
    NCT06759064

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东大学齐鲁医院济南

  9. 正在招募
    First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
    分期
    未注明
    开始
    2022-01
    登记号
    NCT06727981

    年龄 18 岁 至 100 岁(登记的条件)

    牵头:山东大学齐鲁医院济南

  10. 即将招募
    One-Click Autofocus Versus Segmented Focus in Gastric Endoscopy
    分期
    不分期
    开始
    2026-06
    登记号
    NCT07664813

    年龄 18 岁 至 未注明(登记的条件)

    牵头:山东大学齐鲁医院济南

  11. 即将招募
    Multi-center Prospective Validation of Real-Time AI-EGGIM System
    分期
    未注明
    开始
    2026-11
    登记号
    NCT07915843

    年龄未注明(登记的条件)

    牵头:山东大学齐鲁医院济南

  12. 即将招募
    Evaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer
    分期
    不分期
    开始
    2024-05
    登记号
    NCT06421220

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:山东大学齐鲁医院济南

  13. 邀请入组
    Early Postoperative Intervention in Gastric Cancer Patients
    分期
    不分期
    开始
    2026-02
    登记号
    NCT07444099

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:山东大学齐鲁医院济南

  14. 邀请入组
    Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer
    分期
    I期
    开始
    2025-10
    登记号
    NCT07488312

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:山东大学齐鲁医院济南

  15. 邀请入组
    Prolonged Extubation in Gastric Cancer With OSA
    分期
    未注明
    开始
    2023-01
    登记号
    NCT07362706

    年龄 18 岁 至 85 岁(登记的条件)

    牵头:山东大学齐鲁医院济南

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题早期发现与内镜腹膜转移与晚期免疫与靶向药物
论文中的科室消化/肝病科病理/检验科普外/肝胆胰外科肿瘤内科
牵头的论文80
  1. LINC 02086, a novel biomarker for early detection of gastric cancer and a target for cancer therapy.2026Cell death and differentiation
  2. OR2T6 modulates autophagy through the PPP3CA-mediated pathways to suppress gastric cancer.2026Cell death and differentiation
  3. Safety and efficacy of traction robot-assisted endoscopic submucosal dissection for early gastric cancer: a randomized pilot trial.2026EndoscopyRCT
  4. Genomic landscape of paired primary and peritoneal metastatic lesions in gastric cancer highlights evolutionary dynamics and mutational drivers.2026Journal of advanced research免费全文
  5. Precise Identification of Gastric Cancer Pathological Differentiation Based on Hyperspectral Imaging and Lightweight Deep Learning Models.2026Journal of biophotonics
  6. High sodium intake: a silent killer driving global gastric cancer burden.2025BMC cancer免费全文
  7. Deep learning-aided optical biopsy achieves whole-chain diagnosis of Correa cascade of gastric cancer: a prospective study.2025BMC medicine免费全文
  8. Associations Between Gastroenteropancreatic Neuroendocrine Neoplasms and Inflammatory Factors: Insights From a Two-Sample Mendelian Randomization Analysis.2025Canadian journal of gastroenterology & hepatology免费全文
  9. N6-methyladenosine-regulated exosome biogenesis orchestrates an immunosuppressive pre-metastatic niche in gastric cancer peritoneal metastasis.2025Cancer communications (London, England)免费全文
  10. Simvastatin inhibits PD-L1 via ILF3 to induce ferroptosis in gastric cancer cells.2025Cell death & disease免费全文
  11. SP-1-activated LINC01016 overexpression promotes gastric cancer invasion and metastasis through inhibiting EIF4A3-mediated MMP9 mRNA decay.2025Cell death & disease免费全文
  12. ncRNA-mediated ITGB1 upregulation correlates with poor prognosis and tumor-immune infiltration in gastric cancer.2025European journal of medical research免费全文
  13. Hedyotis diffusa Willd.-Scutellaria barbata D.Don herb pair induces ferroptosis in gastric cancer by inhibiting the PI3K/AKT/HIF-1α pathway.2025Fitoterapia
  14. Survival and multi-omics analysis of immunotherapy-based conversion treatment for initially unresectable gastric cancer.2025Frontiers in immunology免费全文
  15. LncRNAs in serum-derived extracellular vesicles are potential biomarker and correlated with immune infiltration in gastric cancer.2025Frontiers in immunology免费全文
  16. Development and validation of a machine learning model for predicting immune checkpoint inhibitor efficacy in advanced gastric cancer using dynamic changes in peripheral blood clinlabomics data: a retrospective multicenter cohort study.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  17. Optical enhancement with magnification versus white-light endoscopy for detecting gastric intestinal metaplasia and neoplasia: a randomized controlled trial.2025Gastrointestinal endoscopyRCT
  18. Vagus Nerve Preservation for Early Distal Gastric Cancer With Monitoring and Indocyanine Green Labeling: A Randomized Clinical Trial.2025JAMA surgeryRCT免费全文
  19. Comparative analysis of gastrectomy vs endoscopic therapy for T1b gastric cancer: long-term outcomes from a population-based propensity score matched cohort study.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  20. Assessment of intestinal metaplasia at the lesser curvature guides mapping biopsies strategy.2025Scandinavian journal of gastroenterology
  21. Association between gastric polyps and decreased bone mineral density in patients with chronic gastritis.2025Scientific reports免费全文
  22. Application of in vivo traction-assisted resection of large gastric mucosal lesions: a case series (with video).2025Surgical endoscopy
  23. Timing and clinical significance of chemotherapy in patients with resected gastric adenocarcinoma: a population-based cohort study.2025The oncologist免费全文
  24. Development and validation of a predictive model for submucosal fibrosis in patients with early gastric cancer undergoing endoscopic submucosal dissection: experience from a large tertiary center.2024Annals of medicine免费全文
  25. The Impact of Transcriptional Profiling Cadherin Family and Therapeutic Approaches of Gastric Cancer: A Translational Outlook on Multi-omics Data Analysis.2024Applied biochemistry and biotechnology
  26. Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study.2024BMC medicine免费全文
  27. Dual PI3K/mTOR inhibitor PF-04979064 regulates tumor growth in gastric cancer and enhances drug sensitivity of gastric cancer cells to 5-FU.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  28. Harnessing cytokines to optimize chimeric antigen receptor-T cell therapy for gastric cancer: Current advances and innovative strategies.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  29. CMYC-initiated HNF1A-AS1 overexpression maintains the stemness of gastric cancer cells.2024Cell death & disease免费全文
  30. Molecular characterization and clinical relevance of metabolic signature subtypes in gastric cancer.2024Cell reports
  31. Advances in Endoscopic Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms.2024Digestive diseases and sciences
  32. A modified endoscopic full-thickness resection technique: double traction-assisted resection.2024Endoscopy免费全文
  33. Endoscopic submucosal dissection of early gastric angle cancer by using a simplified robot-assisted device for traction.2024Endoscopy免费全文
  34. Identification of necroptosis-associated miRNA signature for predicting prognosis and immune landscape in stomach adenocarcinoma.2024Experimental cell research
  35. Expression and clinical value of CXCR4 in high grade gastroenteropancreatic neuroendocrine neoplasms.2024Frontiers in endocrinology免费全文
  36. Disruption of the gastric epithelial barrier in Correa's cascade: Clinical evidence via confocal endomicroscopy.2024Helicobacter
  37. PIN1P1 is activated by CREB1 and promotes gastric cancer progression via interacting with YBX1 and upregulating PIN1.2024Journal of cellular and molecular medicine免费全文
  38. Single-cell profiling reveals altered immune landscape and impaired NK cell function in gastric cancer liver metastasis.2024Oncogene
  39. Proteomic and serological markers for diagnosing cardia gastric cancer and precursor lesions in a Chinese population.2024Scientific reports免费全文
  40. Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis.2023Annals of surgical oncology
  41. Coexistence of early gastric cancer and benign submucosal lesions mimic invasive cancer: a retrospective multicenter experience.2023BMC gastroenterology免费全文
  42. Goblet cells segmentation from confocal laser endomicroscopy with an improved U-Net.2023Biomedical physics & engineering express
  43. Fusobacterium nucleatum-induced exosomal HOTTIP promotes gastric cancer progression through the microRNA-885-3p/EphB2 axis.2023Cancer science免费全文
  44. POU5F1 promotes the proliferation, migration, and invasion of gastric cancer cells by reducing the ubiquitination level of TRAF6.2023Cell death & disease免费全文
  45. PTPN14 promotes gastric cancer progression by PI3KA/AKT/mTOR pathway.2023Cell death & disease免费全文
  46. TRIM44 regulates tumor immunity in gastric cancer through LOXL2-dependent extracellular matrix remodeling.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  47. Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis.2023Clinical & experimental metastasis
  48. Efficacy of anti-programmed cell death protein 1 monoclonal antibody combined with bevacizumab and/or Pseudomonas aeruginosa injection in transplanted tumor of mouse forestomach carcinoma cell gastric cancer in mice and its mechanism in reg2023Clinical and experimental immunology
  49. Serum extracellular vesicles with NSD1 and FBXO7 mRNA as novel biomarkers for gastric cancer.2023Clinical biochemistry
  50. A novel extracorporeal accessory traction device for gastric endoscopic submucosal dissection.2023Endoscopy免费全文
  51. HRCT1, negatively regulated by miR-124-3p, promotes tumor metastasis and the growth of gastric cancer by activating the ERBB2-MAPK pathway.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  52. Cardia and non-cardia gastric cancer risk associated with Helicobacter pylori in East Asia and the West: A systematic review, meta-analysis, and estimation of population attributable fraction.2023Helicobacter
  53. Transmission routes and patterns of helicobacter pylori.2023Helicobacter
  54. CircHIPK3 contributes to cisplatin resistance in gastric cancer by blocking autophagy-dependent ferroptosis.2023Journal of cellular physiology
  55. A rare case of gastric adenocarcinoma with enteroblastic differentiation presenting as pancreatic hepatoid adenocarcinoma metastases.2023Journal of hepato-biliary-pancreatic sciences
  56. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer.2023Nature communications免费全文
  57. Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms.2023Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  58. Identification and validation of key genes associated with pathogenesis and prognosis of gastric cancer.2023PeerJ免费全文
  59. Color-guided deformable convolution network for intestinal metaplasia severity classification using endoscopic images.2023Physics in medicine and biology
  60. Ox-LDL-mediated ILF3 overexpression in gastric cancer progression by activating the PI3K/AKT/mTOR signaling pathway.2022Aging免费全文
  61. Metabolism reprogramming signature associated with stromal cells abundance in tumor microenvironment improve prognostic risk classification for gastric cancer.2022BMC gastroenterology免费全文
  62. Long noncoding RNA lnc-LEMGC combines with DNA-PKcs to suppress gastric cancer metastasis.2022Cancer letters
  63. Upregulation of CRABP2 by TET1-mediated DNA hydroxymethylation attenuates mitochondrial apoptosis and promotes oxaliplatin resistance in gastric cancer.2022Cell death & disease免费全文
  64. Linc01133 contributes to gastric cancer growth by enhancing YES1-dependent YAP1 nuclear translocation via sponging miR-145-5p.2022Cell death & disease免费全文
  65. lncRNA THAP7-AS1, transcriptionally activated by SP1 and post-transcriptionally stabilized by METTL3-mediated m6A modification, exerts oncogenic properties by improving CUL4B entry into the nucleus.2022Cell death and differentiation免费全文
  66. Double-endoscope assisted endoscopic submucosal dissection for treating gastric neuroendocrine tumor.2022Endoscopy
  67. CPNE1 silencing inhibits cell proliferation and accelerates apoptosis in human gastric cancer.2022European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  68. Effects of enhanced education for patients with the Helicobacter pylori infection: A systematic review and meta-analysis.2022Helicobacter
  69. Association of microRNA polymorphisms with gastric cancer risk in the North Chinese Han population.2022Journal of cancer research and therapeutics
  70. Poor oral hygiene behavior is associated with an increased risk of gastric cancer: A population-based case-control study in China.2022Journal of periodontology
  71. Study on the application of preoperative three-dimensional CT angiography of perigastric arteries in laparoscopic radical gastrectomy.2022Scientific reports免费全文
  72. A novel flexible auxiliary single-arm transluminal endoscopic robot facilitates endoscopic submucosal dissection of gastric lesions (with video).2022Surgical endoscopy
  73. Salivary Fusobacterium nucleatum serves as a potential diagnostic biomarker for gastric cancer.2022World journal of gastroenterology免费全文
  74. Proctotomy leak following laparoscopic total gastrectomy with transrectal specimen extraction for gastric cancer: a case report.2021BMC surgery免费全文
  75. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.2021Biochimica et biophysica acta. Reviews on cancer
  76. Screening for upper gastrointestinal cancers with magnetically controlled capsule gastroscopy: a feasibility study.2021Endoscopy
  77. A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors.2021Frontiers in immunology免费全文
  78. Elevated ZBTB7A expression in the tumor invasive front correlates with more tumor budding formation in gastric adenocarcinoma.2021Journal of cancer research and clinical oncology免费全文
  79. MiR-19a/miR-96-mediated low expression of KIF26A suppresses metastasis by regulating FAK pathway in gastric cancer.2021Oncogene
  80. Influence of Sedation on the Detection Rate of Early Cancer and Precancerous Lesions During Diagnostic Upper Gastrointestinal Endoscopies: A Multicenter Retrospective Study.2021The American journal of gastroenterology
它在 ClinicalTrials.gov 上的全部试验(任何状态)46
  1. Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer正在招募NCT07537348牵头方II期2026-01 启动
  2. Multi-center Prospective Validation of Real-Time AI-EGGIM System即将招募NCT07915843牵头方2026-11 启动
  3. Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer正在招募NCT07635836牵头方不分期2026-05 启动
  4. Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer正在招募NCT07537361牵头方II期2026-01 启动
  5. Early Postoperative Intervention in Gastric Cancer Patients邀请入组NCT07444099牵头方不分期2026-02 启动
  6. Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer邀请入组NCT07488312牵头方I期2025-10 启动
  7. Exploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on Multiomics正在招募NCT05812287牵头方2024-03 启动
  8. Integrative Analysis of Exosome-Mediated Single-Cell Transcriptomics and Proteomics in Gastric Cardia Cancer正在招募NCT06702891牵头方2024-12 启动
  9. Evaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer即将招募NCT06421220牵头方不分期2024-05 启动
  10. Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites正在招募NCT06759064牵头方I/II期2024-09 启动
  11. First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)正在招募NCT06730373牵头方II期2024-10 启动
  12. Prolonged Extubation in Gastric Cancer With OSA邀请入组NCT07362706牵头方2023-01 启动
  13. First-Line and Neoadjuvant Immunotherapy for Gastric Cancer正在招募NCT06727981牵头方2022-01 启动
  14. Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer进行中,不再招募NCT06609759牵头方2024-01 启动
  15. Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer进行中,不再招募NCT06157216牵头方不分期2023-10 启动
  16. First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer进行中,不再招募NCT05586061牵头方II期2023-02 启动
  17. Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy进行中,不再招募NCT05585580牵头方II期2023-03 启动
  18. Neoadjuvant Immunotherapy for Resectable Gastric Cancer已完成NCT03878472牵头方II期2019-04 启动
  19. Significance of Circulating Tumor Cells in the Treatment of Gastric and Rectal Cancer已完成NCT02955173牵头方不分期2016-12 启动
  20. One-Click Autofocus Versus Segmented Focus in Gastric Endoscopy即将招募NCT07664813牵头方(推断)不分期2026-06 启动
  21. Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer正在招募NCT06748352牵头方(推断)不分期2024-12 启动
  22. AI-assisted White Light Endoscopy to Identify the Kimura-Takemoto Classification of Atrophic Gastritis状态不明NCT05916014牵头方(推断)2023-06 启动
  23. Artificial Intelligence Confocal Laser Endomicroscopy for Real-time Assessment of Gastric Cancer Risk.状态不明NCT05459428牵头方(推断)2022-05 启动
  24. Artificial Intelligence-assisted Confocal Laser Endomicroscopy Identification of Intestinal Metaplasia Severity状态不明NCT05462743牵头方(推断)2022-07 启动
  25. Different Endoscopic Gastric Cancer Risk Assessments状态不明NCT05458388牵头方(推断)不分期2022-07 启动
  26. Automatic Evaluation of the Severity of Gastric Intestinal Metaplasia With Pathology Artificial Intelligence Diagnosis System状态不明NCT05447221牵头方(推断)2022-08 启动
  27. AQCS for Detection of Early Cancer and Precancerous Lesions on Upper Gastrointestinal Tract已完成NCT04720924牵头方(推断)不分期2021-01 启动
  28. Application of Artificial Intelligence for Early Diagnosis of Gastric Cancer During Optical Enhancement Magnifying Endoscopy状态不明NCT04563416牵头方(推断)2020-07 启动
  29. The Diagnostic Ability of White Light Endoscopy and Magnifying Endoscopy With Optical Enhancement System状态不明NCT04411589牵头方(推断)不分期2020-05 启动
  30. Quality Control of Esophagogastroduodenoscopy Using Real-time EGD Auxiliary System已完成NCT03883035牵头方(推断)不分期2019-03 启动
  31. Medical Consortium for Screening Upper Gastrointestinal Cancers With Magnetically Controlled Capsule Gastroscopy状态不明NCT04032353牵头方(推断)不分期2018-12 启动
  32. Endoscopic Ultrasound-guided Needle-based Confocal Laser Endomicroscopy for Diagnosis of Gastric Subepithelial Tumors已完成NCT02936986牵头方(推断)2016-05 启动
  33. Difference of Gastric Microbiota in the Process of Correa's Model.状态不明NCT02833363牵头方(推断)2016-07 启动
  34. High Definition Endoscopy and Optic Enhancement Endoscopy in Gastric Neoplasia: A Prospective Study状态不明NCT02863965牵头方(推断)2016-03 启动
  35. PCLE for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma状态不明NCT02515721牵头方(推断)不分期2014-07 启动
  36. Association Between Confocal Laser Endomicroscopic (CLE) Features and Gastric Mucosal Microbiome状态不明NCT02063932牵头方(推断)2013-12 启动
  37. New Classification of Stomach Using Probe-based Confocal Laser Endomicroscopy已完成NCT01896310牵头方(推断)2013-06 启动
  38. Artificial Intelligence for Determination of Gastroscopy Surveillance Intervals状态不明NCT05631015牵头方(推断)2012-01 启动
  39. Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma状态不明NCT01642797牵头方(推断)不分期2012-08 启动
  40. Confocal Laser Endomicroscopy for in Vivo Molecular Imaging of Gastric Cancer by Targeting MG7-Ag已完成NCT01366586牵头方(推断)2011-05 启动
  41. Detection of Early Gastric Cancers Using Confocal Laser Endomicroscopy已完成NCT00851305牵头方(推断)不分期2008-08 启动
  42. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  43. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs已完成NCT04852679研究中心III期2021-05 启动
  44. Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly Patients已完成NCT05030870研究中心不分期2021-09 启动
  45. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer已终止NCT02867839研究中心III期2017-04 启动
  46. S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma已完成NCT01364376研究中心不分期2011-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年没有牵头肝母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 4 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

济南有 8 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年没有牵头脊索瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 2 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Primary extra-axial chordoma of distal fibula: report of a case].2019Zhonghua bing li xue za zhi = Chinese journal of pathology

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 16 篇,占 0.7%。

牵头论文
16
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 7720222023: 3320232024: 0020242025: 552025

济南有 24 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室儿科

这些论文过半是实验室或动物研究。

牵头的论文16
  1. Dual-release 3D-printed porous Ti-6Al-4V implant with drug-eluting photothermal micro-nanotopographies: combating osteosarcoma recurrence, infections, and enhancing osteogenesis.2026Biomaterials
  2. N6-Methyladenosine modification mediated by METTL3 promotes DNA-PKcs expression to induce anlotinib resistance in osteosarcoma.2025Clinical and translational medicine
  3. CUDC-907 inhibits osteosarcoma through upregulation of PTX3 and inhibition of PI3K-AKT signaling.2025European journal of pharmacology
  4. Gene signatures of m5C regulators may predict prognosis and immunity status of patients with Ewing's sarcoma.2025International immunopharmacology
  5. Ghrelin increases cis-platinum resistance and promotes aggressiveness of osteosarcoma by activating AKT and Wnt/β-catenin pathways.2025Journal of orthopaedic surgery and research
  6. Osteopontin derived from hypoxia-induced M2 macrophages promotes osteosarcoma progression through modulation of EGR3/ISG15 signaling and RIG-I expression.2025Journal of translational medicine
  7. DEPDC1 as a crucial factor in the progression of human osteosarcoma.2023Cancer medicine
  8. Eicosapentaenoic acid enhances the sensitivity of osteosarcoma to cisplatin by inducing ferroptosis through the DNA-PKcs/AKT/NRF2 pathway and reducing PD-L1 expression to attenuate immune evasion.2023International immunopharmacology
  9. Piperine improves the sensitivity of osteosarcoma cells to doxorubicin by inducing apoptosis and inhibiting the PI3K/AKT/GSK-3β pathway.2023Journal of orthopaedic surgery and research
  10. STEAP2 promotes osteosarcoma progression by inducing epithelial-mesenchymal transition via the PI3K/AKT/mTOR signaling pathway and is regulated by EFEMP2.2022Cancer biology & therapy
  11. SIRT2 promotes the viability, invasion and metastasis of osteosarcoma cells by inhibiting the degradation of Snail.2022Cell death & disease
  12. LINC00313 facilitates osteosarcoma carcinogenesis and metastasis through enhancing EZH2 mRNA stability and EZH2-mediated silence of PTEN expression.2022Cellular and molecular life sciences : CMLS
  13. Identification of Key Genes and miRNAs Affecting Osteosarcoma Based on Bioinformatics.2022Disease markers
  14. In situ Co-Delivery of Doxorubicin and Cisplatin by Injectable Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment.2022International journal of nanomedicine
  15. Discovery and Characterization of Intercondylar Transphyseal Complexes and their Oncological Significance in Transphyseal Extension of Pediatric Osteosarcoma.2022Orthopaedic surgery
  16. Asiaticoside reverses M2 phenotype macrophage polarization-evoked osteosarcoma cell malignant behaviour by TRAF6/NF-κB inhibition.2022Pharmaceutical biology
早期论文(2016–2020 年)18
  1. Wnt/β‑catenin signaling modulates piperine‑mediated antitumor effects on human osteosarcoma cells.2020Molecular medicine reports
  2. CD271 antibody-functionalized HGNs for targeted photothermal therapy of osteosarcoma stem cells.2020Nanotechnology
  3. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma.2020Oncology reports
  4. Long non-coding RNA TUSC7 suppresses osteosarcoma by targeting miR-211.2019Bioscience reports
  5. MicroRNA-99b predicts clinical outcome of osteosarcoma and suppresses tumor cell proliferation, migration and invasion.2019Diagnostic pathology
  6. Downregulation of UBE2T can enhance the radiosensitivity of osteosarcoma in vitro and in vivo.2019Epigenomics
  7. Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway.2018Bioscience reports
  8. MicroRNA-645 promotes metastasis of osteosarcoma via targeting tumor suppressor NM23 nucleoside diphosphate kinase 2.2018Clinical and experimental pharmacology & physiology
  9. Identifying osteosarcoma metastasis associated genes by weighted gene co-expression network analysis (WGCNA).2018Medicine
  10. MicroRNA‑34b promotes proliferation, migration and invasion of Ewing's sarcoma cells by downregulating Notch1.2018Molecular medicine reports
  11. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.2018Molecular medicine reports
  12. EWS-FLI1 positively regulates autophagy by increasing ATG4B expression in Ewing sarcoma cells.2017International journal of molecular medicine
  13. Fibulin-4 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition via the PI3K/Akt/mTOR pathway.2017International journal of oncology
  14. Inhibition of autophagy and enhancement of endoplasmic reticulum stress increase sensitivity of osteosarcoma Saos-2 cells to cannabinoid receptor agonist WIN55,212-2.2016Cell biochemistry and function
  15. HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies.2016Medicine
  16. MicroRNA-181a promotes proliferation and inhibits apoptosis by suppressing CFIm25 in osteosarcoma.2016Molecular medicine reports
  17. Downregulation of DNA-PKcs suppresses P-gp expression via inhibition of the Akt/NF-κB pathway in CD133-positive osteosarcoma MG-63 cells.2016Oncology reports
  18. Diallyl trisulfide induces osteosarcoma cell apoptosis through reactive oxygen species-mediated downregulation of the PI3K/Akt pathway.2016Oncology reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma即将招募NCT05590572研究中心I/II期2023-01 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 4 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.4%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 0020232024: 1120242025: 002025

济南有 9 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科影像/核医学科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

济南有 5 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.2%。

牵头论文
3
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 222025

济南有 7 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
    分期
    未注明
    开始
    2023-11
    登记号
    NCT06039735

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:山东大学齐鲁医院济南

  2. 正在招募
    Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2026-03
    登记号
    NCT07529782

    年龄 未注明 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、杭州、济南、苏州

  3. 正在招募
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07555938

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南京、天津、广州、昆明、杭州、武汉、济南、温州、苏州、青岛

  4. 正在招募
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    分期
    III期
    开始
    2022-09
    登记号
    NCT05243797

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、杭州、武汉、沈阳、济南、温州、郑州、长春

  5. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层复发与耐药干细胞移植
牵头的论文3
  1. Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma.2025BMC cancer免费全文
  2. Prognostic Implications of Thrombocytopenia in Chinese Patients With Newly Diagnosed Multiple Myeloma.2025Cancer medicine免费全文
  3. Refractory primary extramedullary plasmacytoma in kidney: a case report.2021The Journal of international medical research免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
  1. Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma正在招募NCT06039735牵头方2023-11 启动
  2. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma正在招募NCT07555938研究中心III期2026-06 启动
  3. Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma正在招募NCT07529782研究中心I期2026-03 启动
  4. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation正在招募NCT05243797研究中心III期2022-09 启动
  5. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  6. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  7. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  8. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma状态不明NCT05236621研究中心III期2021-01 启动
  9. SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies进行中,不再招募NCT04684108研究中心I期2021-11 启动
  10. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  11. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动
  12. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)已终止NCT01947309研究中心2013-11 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

济南有 2 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-01
    登记号
    NCT06764238

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 24 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、深圳、福州、苏州、西安、贵阳、重庆、长沙、青岛

  2. 正在招募
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-03
    登记号
    NCT06882057

    年龄 1 岁 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 23 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、福州、苏州、西安、贵阳、重庆、长沙、青岛

  3. 正在招募
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    分期
    III期
    开始
    2025-03
    登记号
    NCT07152041

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 20 家列出的医院为研究中心上海、南京、南昌、天津、广州、成都、武汉、济南、深圳、福州、苏州、贵阳、重庆、长沙、青岛

  4. 正在招募
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    分期
    未注明
    开始
    2024-06
    登记号
    NCT06450067

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、天津、广州、徐州、成都、武汉、济南、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题儿童
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.7%。

牵头论文
3
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025

济南有 6 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
研究主题儿童促血小板生成药物
论文中的科室临床试验/研究机构消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

济南有 2 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题儿童EB病毒与感染诱因
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年没有牵头β 地中海贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 3 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

济南有 3 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录
牵头的论文2
  1. Application of Gene Therapy in Hemophilia.2022Current medical science
  2. Diagnosis and treatment of acquired factor VIII deficiency: a case report and literature review.2022The Journal of international medical research

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 7 篇,占 1.4%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 2220232024: 1120242025: 222025

济南有 3 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断急性发作治疗影像
论文中的科室神经内科影像/核医学科肾内科眼科/神经眼科
牵头的论文7
  1. CFHR2 supplementation mitigates pathologies of neuromyelitis optica by regulating complement activation.2025Molecular therapy : the journal of the American Society of Gene Therapy
  2. MRI-based radiomics for differention of aquaporin 4-immunoglobulin G-positive neuromyelitis optic spectrum disorder and anti myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder.2025Multiple sclerosis and related disorders
  3. Factors associated with disease relapse rate in the Neuromyelitis optica spectrum disorder.2024The International journal of neuroscience
  4. Systemic inflammation response index is a useful indicator in distinguishing MOGAD from AQP4-IgG-positive NMOSD.2023Frontiers in immunology免费全文
  5. Evaluation of microvascular changes in the retina and choriocapillaris in primary glaucoma and neuromyelitis optica spectrum disorder with optical coherence tomography angiography.2023Photodiagnosis and photodynamic therapy
  6. Effect of low-dose rituximab treatment on autoimmune nodopathy with anti-contactin 1 antibody.2022Frontiers in immunology免费全文
  7. Neuromyelitis optica spectrum disorder with active replication of hepatitis B virus and seropositive anti-aquaporin-4 antibody: A case report.2021Medicine免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)正在招募NCT06413654研究中心II/III期2024-07 启动
  2. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders进行中,不再招募NCT06044350研究中心II期2023-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.2%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 0020232024: 1120242025: 112025

济南有 4 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
    分期
    I期
    开始
    2025-03
    登记号
    NCT06688435

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心济南

  2. 正在招募
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    分期
    III期
    开始
    2021-07
    登记号
    NCT04951622

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、济南、福州、西安、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题常规免疫治疗眼肌型重症肌无力抗体与诊断
论文中的科室神经内科
牵头的论文6
  1. Clinicopathological profiling and prognosis of idiopathic inflammatory myopathy overlapping with myasthenia gravis: a retrospective cohort study.2025Journal of neurology
  2. Rs1800629 polymorphism in TNF-alpha is associated with the susceptibility and initial short-term glucocorticoids efficacy in myasthenia gravis patients.2024Journal of neuroimmunology
  3. Optimization of the cut-offs in acetylcholine receptor antibodies and diagnostic performance in myasthenia gravis patients.2022Clinica chimica acta; international journal of clinical chemistry
  4. Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study.2022Frontiers in immunology免费全文
  5. Isolated dysarthria as the sole manifestation of myasthenia gravis: a case report.2022The Journal of international medical research免费全文
  6. Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients.2021Journal of neuroimmunology
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis正在招募NCT06688435研究中心I期2025-03 启动
  2. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis正在招募NCT04951622研究中心III期2021-07 启动
  3. A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)进行中,不再招募NCT06456580研究中心III期2024-07 启动
  4. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis进行中,不再招募NCT06298552研究中心III期2024-04 启动
  5. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis进行中,不再招募NCT06558279研究中心III期2024-09 启动
  6. Study of Telitacicept in Generalized Myasthenia Gravis已完成NCT05737160研究中心III期2023-03 启动
  7. A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis进行中,不再招募NCT05070858研究中心III期2021-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 8 篇,占 3.0%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 1120232024: 3320242025: 112025

济南有 5 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文8
  1. Elevated Prolactin Levels Are Associated With Increased Severity and Psychiatric Symptoms in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.2025Brain and behavior
  2. Inhibition of NLRP3 inflammasome alleviates cognitive deficits in a mouse model of anti-NMDAR encephalitis induced by active immunization.2024International immunopharmacology
  3. Rapamycin alleviates mitochondrial dysfunction in anti-NMDAR encephalitis mice.2024International immunopharmacology
  4. Efficacy and Safety of Rituximab Treatment for Anti-N-Methyl-d-Aspartate Receptor Encephalitis Without Tumor in Children.2024Pediatric neurology
  5. Elevated cerebrospinal fluid YKL-40 levels in patients with anti-gamma-aminobutyric- acid-B receptor encephalitis.2023Journal of neuroimmunology
  6. Coexistence of NMDAR, GAD65, and SOX1 antibody-associated autoimmune encephalitis.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  7. Recurrent anti-AMPA receptor encephalitis associated with thymus cancer.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  8. Long-term follow-up of a child with anti-AMPA receptor encephalitis.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
早期论文(2016–2020 年)2
  1. Clinical and EEG characteristics analysis of autoimmune encephalitis in children with positive and negative anti-N-methyl- D-aspartate receptor antibodies.2020Annals of palliative medicine
  2. Anti-N-methyl-D-aspartate receptor encephalitis: A case report.2018Medicine

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝包虫病

Hepatic echinococcosis

2021–2025 年中国大陆作者发表的 152 篇肝包虫病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

济南有 1 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 1120242025: 112025

济南有 9 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文4
  1. Transcription factor MEOX1 accelerates pulmonary fibrosis by regulating mitophagy and senescence.2025European journal of pharmacology
  2. circGRHPR inhibits aberrant epithelial-mesenchymal transformation progression of lung epithelial cells associated with idiopathic pulmonary fibrosis.2024Cell biology and toxicology
  3. The role of autophagy in idiopathic pulmonary fibrosis: from mechanisms to therapies.2022Therapeutic advances in respiratory disease
  4. Secondary organizing pneumonia following occupational acute nitrogen oxide poisoning: a case report.2021The Journal of international medical research
早期论文(2016–2020 年)1
  1. Weighted Gene Coexpression Network Analysis Identifies Key Genes and Pathways Associated with Idiopathic Pulmonary Fibrosis.2019Medical science monitor : international medical journal of experimental and clinical research
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  2. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis已终止NCT06097260研究中心II期2023-11 启动
  3. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05938920研究中心II期2023-06 启动
  4. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04552899研究中心III期2021-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肺淋巴管平滑肌瘤病

Lymphangioleiomyomatosis

2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 1 篇,占 2.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

济南有 2 家医院列在肺淋巴管平滑肌瘤病下全国有 28 家医院列在肺淋巴管平滑肌瘤病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科
牵头的论文1
  1. Multisystem Lymphangioleiomyomatosis.2024Radiology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 13 篇,占 1.7%。

牵头论文
13
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 1120232024: 4420242025: 442025

济南有 8 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文13
  1. Connectivity-based striatal subregion microstructural changes in sporadic amyotrophic lateral sclerosis patients: Relation to motor disability, cognitive deficits, and serum biomarkers.2025European journal of neurology
  2. Proximity extension assay reveals serum inflammatory biomarkers in two amyotrophic lateral sclerosis cohorts.2025Neurobiology of disease
  3. CSF Aβ, Tau, Axonal, Synaptic, Glial, Neural, and Inflammatory Biomarkers in Patients With Sporadic Amyotrophic Lateral Sclerosis.2025Neurology
  4. Generation of an induced pluripotent stem cell (iPSC) line (INNDSUi009-A) from a patient with amyotrophic lateral sclerosis due to SOD1 mutation.2025Stem cell research
  5. Glymphatic dysfunction in patients with early-stage amyotrophic lateral sclerosis.2024Brain : a journal of neurology
  6. Abnormal brain functional network dynamics in amyotrophic lateral sclerosis patients with depression.2024Brain imaging and behavior
  7. Elevated peripheral inflammation is associated with choroid plexus enlargement in independent sporadic amyotrophic lateral sclerosis cohorts.2024Fluids and barriers of the CNS
  8. Choroid plexus enlargement in amyotrophic lateral sclerosis patients and its correlation with clinical disability and blood-CSF barrier permeability.2024Fluids and barriers of the CNS
  9. Hypoxia-Induced FUS-circTBC1D14 Stress Granules Promote Autophagy in TNBC.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  10. Amygdala abnormalities across disease stages in patients with sporadic amyotrophic lateral sclerosis.2022Human brain mapping
  11. Clinical and Electrophysiological Features of Chronic Motor Axonal Neuropathy.2022Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
  12. Hypothalamic subregion abnormalities are related to body mass index in patients with sporadic amyotrophic lateral sclerosis.2022Journal of neurology
  13. Hippocampal subfield and anterior-posterior segment volumes in patients with sporadic amyotrophic lateral sclerosis.2021NeuroImage. Clinical
早期论文(2016–2020 年)2
  1. CMAP decrement by low-frequency repetitive nerve stimulation in different hand muscles of ALS patients.2019Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  2. Analysis of clinical and electrophysiological characteristics of 150 patients with amyotrophic lateral sclerosis in China.2019Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年没有牵头脊髓性肌萎缩症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 2 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Adult Spinal Muscular Atrophy (SMA) China Registry进行中,不再招募NCT05618379研究中心2023-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。

牵头论文
1
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

济南有 3 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

庞贝病

Pompe disease

2021–2025 年中国大陆作者发表的 30 篇庞贝病 PubMed 英文论文中,这家医院牵头了 2 篇,占 6.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

济南有 2 家医院列在庞贝病下全国有 30 家医院列在庞贝病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

济南有 4 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

济南有 2 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

济南有 2 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

济南有 12 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    分期
    III期
    开始
    2025-07
    登记号
    NCT06963827

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科
牵头的论文2
  1. Immune cells mediate the effect of plasma lipidomes on IgA nephropathy: a Mendelian randomization study.2025Renal failure
  2. The association of normal-range serum phosphorus with immunoglobulin A nephropathy progression: a retrospective cohort study.2024International urology and nephrology
早期论文(2016–2020 年)1
  1. The protective effect and mechanism of rapamycin in the rat model of IgA nephropathy.2019Renal failure
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy正在招募NCT06963827研究中心III期2025-07 启动
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  3. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动
  4. Atrasentan in Patients With IgA Nephropathy进行中,不再招募NCT04573478研究中心III期2020-12 启动
  5. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动
  6. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 7 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Idiopathic inflammatory myopathies with anti-mitochondrial antibodies: Clinical features and treatment outcomes in a Chinese cohort.2019Neuromuscular disorders : NMD
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)进行中,不再招募NCT05896124研究中心II期2023-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

济南有 2 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    分期
    III期
    开始
    2026-05
    登记号
    NCT07387549

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、天津、广州、济南、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性膈疝

Congenital diaphragmatic hernia

2021–2025 年中国大陆作者发表的 60 篇先天性膈疝 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

济南有 2 家医院列在先天性膈疝下全国有 46 家医院列在先天性膈疝下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.9%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025

济南有 5 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性血管性水肿

Hereditary angioedema

2021–2025 年中国大陆作者发表的 32 篇遗传性血管性水肿 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

济南有 2 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

济南有 2 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
论文中的科室放疗科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 3 篇,占 5.8%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

济南有 1 家医院列在Leber 遗传性视神经病变下全国有 32 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文3
  1. Leber's hereditary optic neuropathy plus dystonia caused by the mitochondrial ND1 gene m.4160 T > C mutation.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  2. Teaching NeuroImage: Leber Hereditary Optic Neuropathy With Longitudinal Spinal Cord Lesion Mimicking Spinal Cord Infarction.2022Neurology
  3. Leber hereditary optic neuropathy and dystonia overlapping mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes due to m.14459G>A mutation.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

山东大学齐鲁医院

Qilu Hospital of Shandong University

济南

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Qilu Hospital; Qilu Hospital (Qingdao); Qilu Hospital of Shandong University (Qingdao); Shandong University Qilu Hospital; Qilu Hospital Affiliated to Shandong University; Second Qilu Hospital of Shandong University; Qilu Hospital of Shan Dong University; Qilu hospital of Shandong University

提出更正下载数据